Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexvix sub-one-hour instillation feasibility in bladder cancer
2026-526917-27-00Phase 2Authorised
- Sponsor
- Institut Paoli-Calmettes
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hexaminolevulinate in bladder cancer, sponsored by Institut Paoli-Calmettes. Primary endpoint: Tumor fluorescence quality at 30 minutes. Planned start Sep 2026; status: authorised.
02
Drugs
hexaminolevulinate
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2026-526917-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526917-27-00.